Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | ACP3 | P15309 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.40 |
| ▸ | POLQ | O75417 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12944873 | 0.82 | CNR2 (0.41) | CRHBPCRHR2ACP3CNR2SMN1; SMN2 | |
| SCHEMBL9286637 | 0.82 | CNR2 (0.41) | CRHBPCRHR2ACP3CNR2SMN1; SMN2 | |
| SCHEMBL12244178 | 0.78 | CES2 (0.42) | CNR2ALDH1A1LMNAGAA | |
| SCHEMBL12244177 | 0.76 | ESR1 (0.39) | ACP3ALDH1A1LMNA | |
| SCHEMBL6167147 | 0.75 | ACP3 (0.43) | CRHBPCRHR2ACP3CNR2SMN1; SMN2 | |
| SCHEMBL8921824 | 0.75 | ACP3 (0.43) | CRHBPCRHR2ACP3CNR2SMN1; SMN2 | |
| SCHEMBL29129004 | 0.74 | ACP3 (0.47) | ACP3CNR2SMN1; SMN2HSD11B1P2RX7 | |
| SCHEMBL27691016 | 0.74 | ACP3 (0.47) | ACP3CNR2SMN1; SMN2HSD11B1P2RX7 | |
| Acetic Acid SCHEMBL10562657 | 0.73 | ACP3 (0.47) | ACP3CNR2SMN1; SMN2HSD11B1P2RX7 | |
| SCHEMBL888787 | 0.73 | POLQ (0.41) | CRHBPCRHR2ACP3CNR2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470889-B2 | Hybrid-ionone and curcumin molecules as anticancer agents | TRT PHARMA INC. (CA) | 2013-06-25 | — | — | US | disclosed |
| US-20110230488-A1 | HYBRID-IONONE AND CURCUMIN MOLECULES AS ANTICANCER AGENTS | TRT PHARMA INC. (CA) | 2011-09-22 | — | — | US | disclosed |
| WO-2010060214-A1 | HYBRID -IONONE AND CURCUMIN MOLECULES AS ANTICANCER AGENTS | TRT PHARMA INC . (CA) | 2010-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230488-A1 | HYBRID-IONONE AND CURCUMIN MOLECULES AS ANTICANCER AGENTS | IKBKG, HSD17B11, IKBKE | CRHBP 746/4885CRHR2 2675/4885ACP3 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.